Vir Biotechnology Inc (VIR)

$8.52 -0.13 (-1.50%)
Market Cap 1.46B
Revenue (ttm) 68.56M
Net Income (ttm) -437.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -638.84%
Debt to Equity Ratio 0.00
Volume 445,577
Avg Vol 1,714,218
Day's Range N/A - N/A
Shares Out 168.65M
Stochastic %K 2%
Beta 1.65
Analysts Strong Sell
Price Target $20.67

Company Profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibod...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 906 4324
Website: www.vir.bio
Address:
1800 Owens Street, Suite 900, San Francisco, United States
jewell69
jewell69 Jun. 8 at 3:20 PM
$VIR ok, Sis is now an owner. 06/08/2026 Buy VIR VIR BIOTECHNOLOGY INC 250 $8.57 -$2,142.50
0 · Reply
jewell69
jewell69 Jun. 8 at 3:08 PM
$VIR trying 2 re-enter 8.57 250 now b a .60 x .61 6/8 11:07 am EDT PREVIOUS PROFIT TAKING 05/22/2026 Sell VIR VIR BIOTECHNOLOGY INC 300 $9.14 $0.12 $2,741.88 More 05/21/2026 Buy VIR VIR BIOTECHNOLOGY INC 300 $9.05 -$2,715.00
0 · Reply
VIR_Tical1
VIR_Tical1 Jun. 8 at 2:57 PM
$VIR a bit of a positive vibe for Monday AM https://finance.yahoo.com/markets/stocks/articles/vir-biotechnology-inc-vir-good-201423806.html
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 4 at 7:32 AM
$VIR Patrick Trucchio H.C.Wainwright has reiterated his buy stance on Vir pt$20.
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 3 at 5:38 PM
$VIR anyone looking to participate in the SpaceX ipo, tempting after seeing the massive gains made from Tesla, biggest problem i see is it being massively oversubscribed and everyone ends up with $100 of shares,if that.
0 · Reply
CapitalMonk
CapitalMonk Jun. 3 at 3:27 PM
$VIR Price: $8.75 (+0.11%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±2.50% RSI: 40.9 | Momentum: Moderate Volume: -65.9% vs avg Volatility: 3.49% Support: $8.52 | Resistance: $10.31 Data and analytics sourced from Given Analytics educational research: https://www.givenanalytics.com/
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 3 at 10:26 AM
$VIR Share Price: $8.74 Contract Selected: Jan 15, 2027 $10 Calls Buy Zone: $1.30 – $1.61 Target Zone: $2.09 – $2.56 Potential Upside: 52% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
JFais
JFais Jun. 2 at 9:12 PM
Baby with the bathwater should be a focus for current scans. Names being hit for no reason even though the story's looking better $VIR another one on my DD list that seems to fit this profile (that I haven't gotten around to yet)
1 · Reply
jewell69
jewell69 Jun. 2 at 4:41 PM
$XBI b 128.17 12:37 pm edt 6/2 also $VIR -2.93% truth b told we own a thimble full of $BIIB -3.08% today. it had that fairly bad bad -6% day about 3 weeks ago, remember. that's when I originally got in. I can remember taking an eyelash of profit in it 2x in May, 2026.
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 2 at 1:40 PM
$VIR looks like this dispute between Vir & Brii Bio is weighing heavy on the share price, both sides have agreed to arbitration prior to court proceedings, let’s hope for a speedy resolution.
1 · Reply
Latest News on VIR
Vir Biotechnology Transcript: AGM 2026

May 26, 2026, 12:00 PM EDT - 13 days ago

Vir Biotechnology Transcript: AGM 2026

Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial

2026-05-18T20:15:10.000Z - 20 days ago

Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial

Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026

May 18, 2026, 4:05 PM EDT - 20 days ago

Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026

Vir Biotechnology Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 7:20 PM EDT - 26 days ago

Vir Biotechnology Transcript: Bank of America Global Healthcare Conference 2026

Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley

2026-05-08T14:13:29.000Z - 4 weeks ago

Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley

Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year

2026-05-07T00:48:04.000Z - 4 weeks ago

Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year

Vir Biotechnology Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Vir Biotechnology Earnings Call Transcript: Q1 2026

Vir Biotechnology Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Vir Biotechnology Earnings release: Q1 2026

Vir Biotechnology Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Vir Biotechnology Slides: Q1 2026

Vir Biotechnology Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Vir Biotechnology Quarterly report: Q1 2026

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 6, 2026, 4:05 PM EDT - 4 weeks ago

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

May 5, 2026, 4:05 PM EDT - 4 weeks ago

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

Apr 23, 2026, 4:05 PM EDT - 6 weeks ago

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

Vir Biotechnology closes global collaboration agreement with Astellas Pharma

2026-04-16T13:17:10.000Z - 7 weeks ago

Vir Biotechnology closes global collaboration agreement with Astellas Pharma

SNY

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

Apr 16, 2026, 8:05 AM EDT - 7 weeks ago

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

Vir Biotechnology Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 7 weeks ago

Vir Biotechnology Proxy statement: Proxy filing

Vir Biotechnology Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 7 weeks ago

Vir Biotechnology Proxy statement: Proxy filing

Vir Biotechnology announces first patient dosed in Phase 1 trial of VIR-5500

2026-04-13T12:40:25.000Z - 2 months ago

Vir Biotechnology announces first patient dosed in Phase 1 trial of VIR-5500

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Apr 13, 2026, 8:05 AM EDT - 2 months ago

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Vir Biotechnology Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 1:40 PM EDT - 3 months ago

Vir Biotechnology Transcript: Leerink Global Healthcare Conference 2026

Vir Biotechnology price target raised to $20 from $15 at H.C. Wainwright

2026-03-04T11:16:01.000Z - 3 months ago

Vir Biotechnology price target raised to $20 from $15 at H.C. Wainwright

Vir Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 3:10 PM EST - 3 months ago

Vir Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference

Vir Biotechnology to Participate in Upcoming Investor Conferences

Feb 26, 2026, 4:05 PM EST - 3 months ago

Vir Biotechnology to Participate in Upcoming Investor Conferences

Vir Biotechnology 17.65M share Secondary priced at $8.50

2026-02-26T11:16:17.000Z - 3 months ago

Vir Biotechnology 17.65M share Secondary priced at $8.50

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

Feb 25, 2026, 10:31 PM EST - 3 months ago

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

Vir Biotechnology announces $200M public offering of common stock

2026-02-24T21:36:44.000Z - 3 months ago

Vir Biotechnology announces $200M public offering of common stock

Vir Biotechnology Announces Proposed Public Offering of Common Stock

Feb 24, 2026, 4:05 PM EST - 3 months ago

Vir Biotechnology Announces Proposed Public Offering of Common Stock

Vir Biotechnology price target raised to $30 from $26 at Barclays

2026-02-24T19:25:40.000Z - 3 months ago

Vir Biotechnology price target raised to $30 from $26 at Barclays

Vir Biotechnology price target raised to $18 from $14 at Needham

2026-02-24T14:37:22.000Z - 3 months ago

Vir Biotechnology price target raised to $18 from $14 at Needham

Why Is Vir Biotechnology Stock Up Today?

2026-02-24T13:19:50.000Z - 3 months ago

Why Is Vir Biotechnology Stock Up Today?

Vir Biotechnology price target raised to $18 from $12 at Evercore ISI

2026-02-24T13:07:57.000Z - 3 months ago

Vir Biotechnology price target raised to $18 from $12 at Evercore ISI

Vir Biotechnology price target raised to $17 from $13 at BofA

2026-02-24T12:07:35.000Z - 3 months ago

Vir Biotechnology price target raised to $17 from $13 at BofA

Vir Biotechnology Slides: Corporate presentation

Feb 24, 2026, 7:00 AM EST - 3 months ago

Vir Biotechnology Slides: Corporate presentation

Vir Biotechnology price target raised to $24 from $20 at Morgan Stanley

2026-02-24T11:50:12.000Z - 3 months ago

Vir Biotechnology price target raised to $24 from $20 at Morgan Stanley

Vir Biotechnology upgraded to Strong Buy from Outperform at Raymond James

2026-02-24T11:10:14.000Z - 3 months ago

Vir Biotechnology upgraded to Strong Buy from Outperform at Raymond James

What's Happening With VIR Stock?

Feb 24, 2026, 4:10 AM EST - 3 months ago

What's Happening With VIR Stock?

Vir Biotechnology Earnings Call Transcript: Q4 2025

Feb 23, 2026, 5:30 PM EST - 3 months ago

Vir Biotechnology Earnings Call Transcript: Q4 2025

Vir Biotechnology Annual report: Q4 2025

Feb 23, 2026, 5:30 PM EST - 3 months ago

Vir Biotechnology Annual report: Q4 2025

Vir Biotechnology Earnings release: Q4 2025

Feb 23, 2026, 5:30 PM EST - 3 months ago

Vir Biotechnology Earnings release: Q4 2025

Vir Biotechnology Slides: Q4 2025

Feb 23, 2026, 5:30 PM EST - 3 months ago

Vir Biotechnology Slides: Q4 2025

Vir Biotechnology reports Q4 EPS (31c), consensus (50c)

2026-02-23T22:20:15.000Z - 3 months ago

Vir Biotechnology reports Q4 EPS (31c), consensus (50c)

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 23, 2026, 5:14 PM EST - 3 months ago

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Vir Biotechnology reports new VIR-5500 data

2026-02-23T22:10:34.000Z - 3 months ago

Vir Biotechnology reports new VIR-5500 data

Astellas collaborates with Vir to develop its experimental prostate cancer drug

Feb 23, 2026, 5:08 PM EST - 3 months ago

Astellas collaborates with Vir to develop its experimental prostate cancer drug

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Feb 23, 2026, 5:02 PM EST - 3 months ago

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer

Feb 23, 2026, 5:00 PM EST - 3 months ago

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer

Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results

Feb 9, 2026, 4:05 PM EST - 4 months ago

Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results

Vir Biotechnology Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:45 PM EST - 5 months ago

Vir Biotechnology Transcript: 44th Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:45 PM EST - 5 months ago

Vir Biotechnology Slides: 44th Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

Jan 12, 2026, 8:00 AM EST - 5 months ago

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:05 PM EST - 5 months ago

Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program

Dec 16, 2025, 4:05 PM EST - 6 months ago

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program

Vir Biotechnology Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 10:50 AM EST - 6 months ago

Vir Biotechnology Transcript: Evercore ISI 8th Annual HealthCONx Conference

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

Nov 19, 2025, 4:05 PM EST - 7 months ago

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

Vir Biotechnology Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 9:00 AM EST - 7 months ago

Vir Biotechnology Transcript: Jefferies London Healthcare Conference 2025

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

Nov 9, 2025, 6:07 PM EST - 7 months ago

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Nov 7, 2025, 9:00 AM EST - 7 months ago

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Vir Biotechnology Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 7 months ago

Vir Biotechnology Earnings Call Transcript: Q3 2025

Vir Biotechnology Quarterly report: Q3 2025

Nov 5, 2025, 4:30 PM EST - 7 months ago

Vir Biotechnology Quarterly report: Q3 2025

Vir Biotechnology Earnings release: Q3 2025

Nov 5, 2025, 4:30 PM EST - 7 months ago

Vir Biotechnology Earnings release: Q3 2025

Vir Biotechnology Slides: Q3 2025

Nov 5, 2025, 4:30 PM EST - 7 months ago

Vir Biotechnology Slides: Q3 2025

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 7 months ago

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

Nov 3, 2025, 8:00 AM EST - 7 months ago

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 22, 2025, 4:05 PM EDT - 8 months ago

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

Oct 9, 2025, 4:05 PM EDT - 8 months ago

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025

Oct 7, 2025, 8:00 AM EDT - 8 months ago

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 25, 2025, 4:05 PM EDT - 10 months ago

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Vir Biotechnology Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Vir Biotechnology Earnings Call Transcript: Q2 2025

Vir Biotechnology Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Vir Biotechnology Quarterly report: Q2 2025

Vir Biotechnology Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Vir Biotechnology Earnings release: Q2 2025

Vir Biotechnology Slides: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Vir Biotechnology Slides: Q2 2025

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 4:05 PM EDT - 10 months ago

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Aug 6, 2025, 8:05 AM EDT - 10 months ago

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Jul 31, 2025, 8:05 AM EDT - 11 months ago

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Jul 24, 2025, 8:05 AM EDT - 11 months ago

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 22, 2025, 4:05 PM EDT - 11 months ago

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

20 stocks you should avoid — no matter how well the market does

Jun 11, 2025, 7:00 AM EDT - 1 year ago

20 stocks you should avoid — no matter how well the market does

CORT CPRX CRK CRNC DDD LUMN LYV

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 28, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Vir Biotechnology Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 27, 2025, 4:30 PM EDT - 1 year ago

Vir Biotechnology Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

May 20, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

Vir Biotechnology Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 4:40 PM EDT - 1 year ago

Vir Biotechnology Transcript: BofA Securities 2025 Healthcare Conference

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 12, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 9, 2025, 6:00 AM EDT - 1 year ago

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

Vir Biotechnology Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Vir Biotechnology Earnings Call Transcript: Q1 2025

Vir Biotechnology Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Vir Biotechnology Quarterly report: Q1 2025

Vir Biotechnology Earnings release: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Vir Biotechnology Earnings release: Q1 2025

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Apr 24, 2025, 9:30 AM EDT - 1 year ago

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Vir Biotechnology Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Vir Biotechnology Proxy statement: Proxy Filing

Vir Biotechnology Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Vir Biotechnology Proxy statement: Proxy Filing

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Mar 21, 2025, 7:10 AM EDT - 1 year ago

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Mar 13, 2025, 8:05 AM EDT - 1 year ago

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Vir Biotechnology Earnings Call Transcript: Q4 2024

Vir Biotechnology Annual report: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Vir Biotechnology Annual report: Q4 2024

Vir Biotechnology Earnings release: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Vir Biotechnology Earnings release: Q4 2024

Vir Biotechnology Slides: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Vir Biotechnology Slides: Q4 2024

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 4:05 PM EST - 1 year ago

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Feb 19, 2025, 4:05 PM EST - 1 year ago

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Feb 12, 2025, 4:05 PM EST - 1 year ago

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Vir Biotechnology Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 7:30 PM EST - 1 year ago

Vir Biotechnology Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Vir Biotechnology Slides: FY 2025

Jan 14, 2025, 7:30 PM EST - 1 year ago

Vir Biotechnology Slides: FY 2025

Vir Biotechnology Transcript: Status Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Vir Biotechnology Transcript: Status Update

Vir Biotechnology Press release: Status Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Vir Biotechnology Press release: Status Update

Vir Biotechnology Slides: Status Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Vir Biotechnology Slides: Status Update

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Jan 8, 2025, 7:45 AM EST - 1 year ago

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 9:30 AM EST - 1 year ago

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Dec 12, 2024, 4:05 PM EST - 1 year ago

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Vir Biotechnology Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 9:10 AM EST - 1 year ago

Vir Biotechnology Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Nov 26, 2024, 9:30 AM EST - 1 year ago

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 25, 2024, 9:30 AM EST - 1 year ago

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

jewell69
jewell69 Jun. 8 at 3:20 PM
$VIR ok, Sis is now an owner. 06/08/2026 Buy VIR VIR BIOTECHNOLOGY INC 250 $8.57 -$2,142.50
0 · Reply
jewell69
jewell69 Jun. 8 at 3:08 PM
$VIR trying 2 re-enter 8.57 250 now b a .60 x .61 6/8 11:07 am EDT PREVIOUS PROFIT TAKING 05/22/2026 Sell VIR VIR BIOTECHNOLOGY INC 300 $9.14 $0.12 $2,741.88 More 05/21/2026 Buy VIR VIR BIOTECHNOLOGY INC 300 $9.05 -$2,715.00
0 · Reply
VIR_Tical1
VIR_Tical1 Jun. 8 at 2:57 PM
$VIR a bit of a positive vibe for Monday AM https://finance.yahoo.com/markets/stocks/articles/vir-biotechnology-inc-vir-good-201423806.html
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 4 at 7:32 AM
$VIR Patrick Trucchio H.C.Wainwright has reiterated his buy stance on Vir pt$20.
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 3 at 5:38 PM
$VIR anyone looking to participate in the SpaceX ipo, tempting after seeing the massive gains made from Tesla, biggest problem i see is it being massively oversubscribed and everyone ends up with $100 of shares,if that.
0 · Reply
CapitalMonk
CapitalMonk Jun. 3 at 3:27 PM
$VIR Price: $8.75 (+0.11%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±2.50% RSI: 40.9 | Momentum: Moderate Volume: -65.9% vs avg Volatility: 3.49% Support: $8.52 | Resistance: $10.31 Data and analytics sourced from Given Analytics educational research: https://www.givenanalytics.com/
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 3 at 10:26 AM
$VIR Share Price: $8.74 Contract Selected: Jan 15, 2027 $10 Calls Buy Zone: $1.30 – $1.61 Target Zone: $2.09 – $2.56 Potential Upside: 52% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
JFais
JFais Jun. 2 at 9:12 PM
Baby with the bathwater should be a focus for current scans. Names being hit for no reason even though the story's looking better $VIR another one on my DD list that seems to fit this profile (that I haven't gotten around to yet)
1 · Reply
jewell69
jewell69 Jun. 2 at 4:41 PM
$XBI b 128.17 12:37 pm edt 6/2 also $VIR -2.93% truth b told we own a thimble full of $BIIB -3.08% today. it had that fairly bad bad -6% day about 3 weeks ago, remember. that's when I originally got in. I can remember taking an eyelash of profit in it 2x in May, 2026.
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 2 at 1:40 PM
$VIR looks like this dispute between Vir & Brii Bio is weighing heavy on the share price, both sides have agreed to arbitration prior to court proceedings, let’s hope for a speedy resolution.
1 · Reply
Dunnieboy1
Dunnieboy1 Jun. 1 at 7:45 PM
$VIR a great recommendation from a highly regarded wall st analyst today, and we drop over 5%, crazy business.
0 · Reply
deezstocks3
deezstocks3 Jun. 1 at 6:53 PM
$VIR bought some more today. 😎 GLTA
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 1 at 9:43 AM
$VIR Etzer Darout of Barclays has just put out a buy recommendation at $30
0 · Reply
Dunnieboy1
Dunnieboy1 May. 30 at 8:02 PM
$VIR in June 2024 we our Hepatitis drugs received fast track designation, i wonder were we are up to with that program; Yes, Vir Biotechnology’s combination therapy of tobevibart and elebsiran (for the treatment of chronic hepatitis delta infection) still retains its FDA Fast Track designation.The therapy is currently advancing through its global Phase 3 ECLIPSE registrational trials and continues to be supported by this designation, which is designed to expedite the development and review of drugs addressing serious unmet medical needs. In addition to Fast Track, the drug combination also holds an FDA Breakthrough Therapy designation.
0 · Reply
sittingonagoldmine
sittingonagoldmine May. 29 at 9:14 PM
$VIR So astonishing 88% reach target-not-detected (no HDV virus) after 2 years of treatment. Look at the steady increase from 1y of treatment to the 2y treatment period for the combo tob&elebs. Very good results in my humble opinion! To me, this is a confirmation that they have a very reliable and safe HDV treatment. I hope they push fast through Phase III. Seems like a real buying opportunity when the stock goes down.... Good luck to all VIR long-term bulls!
1 · Reply
VIR_Tical1
VIR_Tical1 May. 29 at 8:46 PM
$VIR https://www.ajmc.com/view/tobevibart-elebsiran-sustains-hdv-suppression-at-96-weeks-tarik-asselah-md-phd
0 · Reply
Dunnieboy1
Dunnieboy1 May. 29 at 4:39 PM
$VIR what time uk is the data out?
1 · Reply
Dunnieboy1
Dunnieboy1 May. 29 at 2:56 PM
$VIR we may get to finish way above $10 if the data release is extremely positive & hold it going into the weekend, most of our positive news comes after the bell and the price flies up in after hours trading then settles down in pre-market trading the next day. Could fly.
0 · Reply
VIR_Tical1
VIR_Tical1 May. 29 at 11:39 AM
$VIR The 96-week data from Vir Biotechnology’s Phase 2 SOLSTICE trial (tobevibart + elebsiran combination for chronic Hepatitis D / HDV) is being presented today at EASL Congress 2026 in an oral session selected for 🗣️ “Best of EASL 2026.” Today’s presentation could be a key catalyst. Looking for: Confirmation of strong efficacy ( in the 80-90%+ range for key viral endpoints in evaluable patients), good tolerability, and clinical meaningfulness for a potential new standard-of-care option in chronic HDV (an area with high unmet need). Strong full results (high response durability + clean safety) which could support further upside, especially if the program reveals Breakthrough Therapy Designation potential providing a clear path to registrational data in 2027.
0 · Reply
metalcook
metalcook May. 29 at 8:04 AM
$VIR Hep B is dead... Long live Hep D! On a serious note, competition is key to real value of VIR. We have beaten JANX with PSMA. JANX was worth 3x what VIR now is worth. No correction happened to VIR valuation unfortunately. Will we beat MIRM with Hep D? MIRM payd 820mil$ (220mil in milestones).
0 · Reply
metalcook
metalcook May. 29 at 6:49 AM
$VIR https://endpoints.news/gsk-spells-out-positive-phase-3-data-for-hepatitis-b-drug-it-licensed-from-ionis/
0 · Reply
McMillion1
McMillion1 May. 26 at 7:14 PM
$VIR what’s being presented today? Is it an after hour boom or bust?
1 · Reply